FDA approved Zanidatamab to treat Advanced Metastatic Biliary Tract Cancers – Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer shared a post on LinkedIn:
“The FDA has approved the drug zanidatamab to treat advanced and metastatic bile duct cancer and other biliary tract cancers that have high levels of a protein called HER2 and do not respond to chemotherapy.
Dr. James Harding, a gastrointestinal medical oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center (MSK), led the trial that resulted in the drug’s approval.
“These cancers are rare, making up just 3% of all gastrointestinal cancers,” Dr. Harding says.
“But MSK is a major center for biliary tract cancer research and treatment. We are evaluating multiple novel treatment approaches, and a key focus of our work is on molecular testing of these tumors and finding ways to target them with precision medicine.””
Learn more.“
For more Updates, Follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023